The impact of chronic lymphocytic leukemia (CLL) therapy on the spectrum of infection.
| Type of treatment . | Spectrum of infection . |
|---|---|
| Single-agent alkylator therapy (+/− corticosteroids) | Common bacterial pathogens |
| Purine analogs | Candida, Aspergillus, herpesviruses, Pneumocystis |
| Monoclonal antibodies | |
| Rituximab | No definitive change in spectrum of infection |
| Alemtuzumab | Herpesviruses, including cytomegalovirus, Candida, Aspergillus, Pneumocystis |
| Type of treatment . | Spectrum of infection . |
|---|---|
| Single-agent alkylator therapy (+/− corticosteroids) | Common bacterial pathogens |
| Purine analogs | Candida, Aspergillus, herpesviruses, Pneumocystis |
| Monoclonal antibodies | |
| Rituximab | No definitive change in spectrum of infection |
| Alemtuzumab | Herpesviruses, including cytomegalovirus, Candida, Aspergillus, Pneumocystis |